Medistim ASA — Cyborg Score 7/10

Strong
Medical Device Manufacturing - Surgical Imaging & Hemodynamic Monitoring

Strategic Profile

In 2023, Medistim significantly grew its direct sales footprint by adding China, Canada, and Sweden to its list of direct countries. Medistim is the market leader in intraoperative ultrasonic guidance and quality assessment focused on improving surgical outcomes. The company combines proprietary TTFM technology with ultrasound imaging in a unified platform designed for intraoperative use.

Cyborg Score Rationale

Medistim holds a defensible market-leading position in a specialized but growing surgical technology segment with global expansion momentum. Recent geographic expansion and Export Award recognition demonstrate execution capability, though scale remains modest relative to larger medtech competitors.

Top Insights

  • Market leadership in niche surgical imaging segment (TTFM) with limited direct competition in core application areas
  • Successful international expansion strategy—added three new direct markets (China, Canada, Sweden) in 2023 and was nominated for National Export Award
  • Dual revenue model combining proprietary MiraQ systems (Own Products) with third-party distributor business (medical device distribution across Nordics)
  • Compact, efficient operating model with ~119 employees generating ~$35M annual revenue (2025), indicating strong margins and operational leverage

Named Competitors

  • Transit Time Flow Measurement Systems — Blood flow measurement technology competitor
  • Hemodynamic Monitoring — Intraoperative monitoring and assessment systems
  • Surgical Imaging & Ultrasound — Broader surgical imaging and equipment manufacturer

Recent Developments

  • (2025) Medistim ASA annual revenue reached $35M across growing geographic footprint
  • (2024) International Women's Day recognition and leadership transitions reflecting organizational maturation
  • (2023) Nomination for National Export Award highlighting global growth trajectory and addition of three new direct sales countries
  • (2023) Revenue of NOK 86 million (~€9M) with AAA credit rating from BISNODE

Open the full interactive Medistim ASA report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →